6 July 2020 – In July 2020, CRISPR Therapeutics AG, Switzerland (Nasdaq: CRSP) (CRISPR) carried out an underwritten offering of 6,982,143 shares (including overallotment shares), resulting in gross proceeds of approximately USD 520 million. Goldman Sachs & Co. LLC, BofA Securities and Jefferies were acting as joint book-running managers for the offering. Canaccord Genuity, William Blair, SunTrust Robinson Humphrey and Roth Capital Partners were acting as co-managers for the offering.

CRISPR is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR is headquartered in Zug, Switzerland. CRISPR’s common shares are listed on Nasdaq.

Walder Wyss acted as Swiss counsel to CRISPR in connection with the transaction. The team was led by Alex Nikitine (Partner, Corporate/M&A, Capital Markets) and Christian Lütolf (Managing Associate, Corporate/M&A, Capital Markets) and further included Rafael Zemp (Managing Associate, Corporate/M&A, Capital Markets), André Kuhn (Managing Associate, Notary), Jasmin Eicher (Trainee, Capital Markets), Maurus Winzap (Partner, Tax) and Janine Corti (Counsel, Tax).